Scopus BioPharma Announces Biotechnology Market Chief Rejoins Board of Directors
NEW YORK, May perhaps 05, 2022 (Globe NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company establishing transformational therapeutics for significant health conditions with sizeable unmet health-related need to have, currently introduced the appointment of Raphael (“Rafi”) Hofstein, Ph.D. to its Board of Directors (“Board”).
Joshua R. Lamstein, Chairman of Scopus BioPharma, mentioned, “We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein delivers invaluable insights and unparalleled expertise in building begin-up biotechnology firms into field leaders.”
Dr. Hofstein is a worldwide leader in the biopharmaceutical and biotechnology industries. Around his career, Dr. Hofstein has been instrumental in the founding and/or management of around 60 biopharmaceutical and biotechnology firms. These companies include things like Fibrocor Therapeutics, a precision medicine corporation BioLineRx (Nasdaq: “BLRX”), a scientific-stage biopharmaceutical firm concentrated on oncology and Encycle Therapeutics, a peptide therapeutics company. Dr. Hofstein is Chairman of Fibrocor, which has strategic partnerships with Evotec SE (Nasdaq: “EVO”) and Galapagos NV (Nasdaq: “GLPG”). Dr. Hofstein has been a director of BioLineRx considering the fact that its inception. Encycle was obtained by Zealand Pharma A/S (Nasdaq: “ZEAL”) in 2019. Dr. Hofstein has also performed critical leadership roles in establishing sector partnerships and strategic alliances with foremost world biopharmaceutical, biotechnology and pharmaceutical firms, like Amgen, Baxter, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer and Takeda.
Dr. Hofstein been given his B.Sc. in Chemistry and Physics from The Hebrew College of Jerusalem and his M.Sc. and Ph.D. in Existence Sciences and Chemistry from the Weizmann Institute of Science. Dr. Hofstein accomplished his postdoctoral instruction and analysis in the Section of Neurobiology at Harvard Health-related College.
Dr. Hofstein said, “I am delighted to resume serving on the Board of Scopus. Owning launched and nurtured lots of prosperous biotech organizations, I am very psyched about the Duet System, which encompasses an excellent and extensive portfolio of immuno-oncology assets.”
Alan Horsager, Ph.D., President – Immuno-Oncology of Scopus BioPharma and President and Main Govt Officer of Duet BioTherapeutics, said, “Dr. Hofstein has supplied extraordinary advice to us, dependent on his knowledge in creating and commercializing novel and distinct drug candidates. He views our bi-useful, TLR9-concentrating on strategy to STAT3 inhibition as a initial-in-course solution to resolve the prolonged-noted problem of STAT3’s undruggability.”
STAT3 has extended been discovered as taking part in a critical job in human cancers, nonetheless it has remained mostly “undruggable” owing to inadequate selectively, potency and deliverability of therapeutics made to target it. The Duet Platform presents a exceptional and highly efficient remedy to the restrictions of targeting STAT3 by using a nucleic acid-dependent suite of molecules which disrupt the protein in a specific, mobile-certain manner whilst at the same time beating one of the main boundaries to effective nucleic acid therapeutics: endosomal escape. This is completed by the inclusion of a TLR9-targeting CpG moiety in Duet’s compounds, enabling their helpful cellular internalization and release with the added reward of endorsing innate and adaptive anti-tumor immune responses.
Dr. Hofstein fills a vacancy on the Board produced by the voluntary resignations of directors who joined the Board as a end result of the contested election relating to the 2021 Yearly Meeting of Stockholders. The benefits of the contested election are staying challenged in an action pursuant to Segment 225 of Delaware’s Normal Corporation Legislation in the Delaware Court of Chancery.
About Scopus BioPharma
Scopus BioPharma Inc., both instantly and by way of subsidiaries, is a biopharmaceutical organization creating transformational therapeutics for really serious disorders with significant unmet healthcare require. Duet BioTherapeutics, a wholly-owned subsidiary of Scopus, was launched in September 2021 by Scopus BioPharma to integrate the immunotherapy assets of Scopus and Olimmune, making the Duet Platform. The Duet Platform is comprised of a few unique complementary CpG-STAT3 inhibitors: RNA silencing – CpG-STAT3siRNA – (“DUET-01”) Antisense – CpG-STAT3ASO – (“DUET-02”) and DNA-binding inhibitor – CpG-STAT3decoy – (“DUET-03”). The Corporation is also developing extra drug candidates and trying to get to detect further compelling systems for opportunity acquisition, in-licensing and/or other related transactions.
Forward-Looking Statements
This press launch may possibly contain forward-looking statements that include hazards and uncertainties. Forward-seeking statements are statements that are not historical info. This kind of forward-hunting statements are topic to challenges (which include individuals set forth in the Company’s Kind 10-K for the fiscal 12 months ended December 31, 2021, as amended, filed with the U.S. Securities and Trade Fee) and uncertainties which could trigger precise success to differ from the ahead-wanting statements. The Enterprise expressly disclaims any obligations or enterprise to launch publicly any updates or revisions to any ahead-searching statements contained herein to mirror any modify in the Company’s anticipations with regard thereto or any transform in gatherings, situations or instances on which any assertion is primarily based. Investors should notice that if our fundamental assumptions for the projections contained herein establish inaccurate or that identified or unfamiliar pitfalls or uncertainties materialize, actual benefits could fluctuate materially from our expectations and projections. More, there can be no assurance that the Corporation will detect and/or consummate any transaction relating to any extra systems.
Contacts
Rodd Leeds/David Waldman

Crescendo Communications, LLC

Tel: (212) 671-1020

E-mail: [email protected]
Hugh Burns/Delia Cannan/Nicholas Leasure

Reevemark

Tel: (212) 433-4600

E mail: [email protected]

